Table 2.

Strategic considerations and implications of personalised medicine

Pharmaceutical companies	• Generate new revenue stream
	• Increased targeted therapies
	• Improve current clinical trials design (kick-off  candidates at phase III)
	• Differentiate CM product offerings
	• Shorten clinical trials
	• Improve go-no-go decisions in clinical trials and  make it earlier
Diagnostic companies	• New pivotal in the personalised medicine
	• Need to establish relationships with  pharmaceutical companies
Payers/health ensurers	• Payers ensure payment of personalised medicine
	• Agree on reimbursement
	• Improve the availability of personalised medicine  and their respective diagnostic
	• Have control over escalating healthcare costs
Regulatory authorities	• Clinical trials with improved statistical relevance
	• Will aid co-development programmes
	• Enhance the utility of test information on product  labelling